Ping Chen

Dr. Ping Chen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Med
Verified
Journal Article
Closed access
ZGZhenming Guo
Zhenming Guo
YLYingchun Luo
Yingchun Luo
YBYan Bi
Yan Bi
LLLiangjie Liu
Liangjie Liu
YQYuan Qi
Yuan Qi
SBShan Bian
Shan Bian

1 March 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
BZBei Zhang
Bei Zhang
QQQi Quan
Qi Quan
QCQi Chen
Qi Chen
PCPing Chen
Ping Chen
LJLi Jiang
Li Jiang
HQHuijuan Qiu
Huijuan Qiu
Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is an invasive lymphoid malignancy with unfavorable survival, for which a prognostic model has not yet been validated. We hypothesized that serum apolipoprotein A-I (ApoA-I) may serve as a novel prognostic marker for ENKTL. Patients and methods: A total of 236 newly diagnosed cases of ENKTL were analyzed retrospectively. Results: The optimal cutoff value for the serum ApoA-I level was determined to be 0.95 g/L. A total of 154 and 82 cases were assigned to the high and low ApoA-I groups, respectively. Patients in the low ApoA-I group tended to present with poorer clinical features, a lower complete remission rate (P=0.001), and poor median progression-free survival (P<0.001) and overall survival (P<0.001). Multivariate analysis using Cox model showed that the serum ApoA-I level was an independent prognostic marker of overall survival (P<0.001) and progression-free survival (P<0.001) for ENKTL patients. For cases in the low-risk group, as assessed by International Prognostic Index, Prognosis Index for peripheral T-cell lymphoma, unspecified, and Korean Prognostic Index, the serum ApoA-I level was able to differentiate cases with poor outcomes from cases with good outcomes. Conclusion: Our results showed that the baseline serum ApoA-I level was helpful for predicting ENKTL prognosis.

15 June 2026 in Cell Death & Disease
Verified
Journal Article
Open access
LQLuomeng Qian
Luomeng Qian
PCPing Chen
Ping Chen
BWBo Wang
Bo Wang
QZQing Zhang
Qing Zhang
YGYuan Guo
Yuan Guo
SZSihe Zhang
Sihe Zhang
Sorafenib is a widely used targeting drug for hepatocellular carcinoma (HCC) patients; however, sorafenib resistance poses a significant clinical challenge. Hypoxia and extracellular vesicles (EVs) induce vasculogenic mimicry (VM) which is linked to sorafenib resistance in HCC. Migrasomes (Migs), the newly discovered large EVs, foster HCC malignant phenotypes by facilitating the intercellular transfer of functional molecules. Despite these advancements, the precise mechanism by which Migs cause sorafenib resistance is still unknown. In this study, we found that hypoxia upregulates the Migs release and CD147 expression on Migs surface, which is related to sorafenib resistance in HCC. Further investigations revealed that hypoxia-induced migrasomes (hypo-Migs) induce VM formation, thereby promoting sorafenib resistance in HCC. Notably, hypo-Migs are internalized into HCC cells through macropinocytosis, which depends on the expression of lysophosphatidic acid receptor 6 (LPAR6). Mechanistically, CD147-positive (CD147 + ) hypo-Migs activate the PI3K/AKT/TWIST1 signaling pathway, subsequently inducing VM formation and promoting sorafenib resistance. Importantly, dual blockade of CD147 + -hypo-Migs macropinocytosis and VM formation enhances the sorafenib-killing efficacy to HCC. Conclusively, our findings uncover a novel sorafenib resistance mechanism induced by CD147 + -hypo-Migs, and highlight dual-targeting of macropinocytosis and VM as a promising strategy to overcome the sorafenib resistance in HCC.

31 October 2024 in BioScience Trends
Verified
Journal Article
Open access
PDF file
ZHZhiqiang Han
Zhiqiang Han
RHRuyu Han
Ruyu Han
YWYimeng Wang
Yimeng Wang
KZKangwei Zhu
Kangwei Zhu
XTXiangdong Tian
Xiangdong Tian
LCLu Chen
Lu Chen
Sorafenib is a recommended first-line therapy for advanced hepatocellular carcinoma (HCC). However, when used as monotherapy in patients in advanced stages, the prognosis remains suboptimal. This study aimed to evaluate the impact of transcatheter arterial chemoembolization (TACE) on survival outcomes in patients with advanced HCC treated with sorafenib, as well as to identify which subgroups may benefit most from the addition of TACE. This single-institution retrospective study included 92 patients diagnosed with Barcelona Clinic liver cancer (BCLC) stage C HCC who received sorafenib between August 2011 and December 2016. We assessed the influence of different treatment modalities on prognosis using multivariable regression analysis. Patients were categorized into three subgroups: those with vascular invasion, those with distant metastasis, and those with both risk factors. Baseline comparisons indicated no significant differences in clinical characteristics among the three groups. Survival analysis showed no statistically significant difference in overall survival (OS) between the subgroups. However, in the overall cohort of patients with BCLC stage C, multifactorial Cox regression analysis identified pre-treatment alpha-fetoprotein (AFP) levels (p = 0.020), alkaline phosphatase (ALP) levels (p = 0.034), and the absence of combination TACE therapy (p = 0.008) as independent risk factors affecting OS. Further subgroup Cox analyses revealed that the lack of combination TACE therapy was an independent risk factor for OS in both the vascular invasion group and the group with both risk factors. In conclusion, for patients with advanced HCC receiving sorafenib, the addition of TACE may enhance long-term survival, particularly in those with vascular invasion.

9 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YLYayue Liu
Yayue Liu
KZKangwei Zhu
Kangwei Zhu
XTXindi Tian
Xindi Tian
PCPing Chen
Ping Chen
QXQingqing Xiong
Qingqing Xiong
TSTianqiang Song
Tianqiang Song
Background: Gallbladder cancer (GBC) is a rare but aggressive malignancy. Prognostic tools are essential for optimizing postoperative treatment strategies. We aim to develop and validate a prognostic nomogram to estimate 1-, 3-, and 5-year overall survival (OS) in GBC patients and explore the role of adjuvant chemotherapy across different subgroups. Methods: A total of 1848 postoperative GBC patients from the SEER database (2000–2020 17 regions) were analyzed, with an additional external validation cohort of 108 patients from China (2010–2020). Prognostic factors were identified using LASSO regression and multivariable Cox analysis. A nomogram was constructed and validated using the concordance index (C-index), time-dependent ROC curves, calibration curves, and decision curve analysis (DCA). Subgroup analyses were performed to evaluate the impact of adjuvant chemotherapy. Results: The nomogram demonstrated strong predictive performance, with C-indices of 0.767 (training), 0.798 (internal validation), and 0.750 (external validation). Time-dependent ROC curves in the training cohort showed AUCs of 0.777, 0.769, and 0.800 for 1-, 3-, and 5-year OS, respectively. In the internal validation cohort, the corresponding AUCs were 0.763, 0.743, and 0.803. External validation using the independent Chinese cohort of 108 patients showed consistent results, with AUCs of 0.771, 0.835, and 0.810 for 1-, 3-, and 5-year OS. Subgroup analysis revealed that adjuvant chemotherapy significantly improved survival in patients with TNM stage >IIB. In contrast, patients with early-stage disease (TNM ≤ IIB) showed no significant survival benefit from chemotherapy. Conclusions: This study developed a validated prognostic nomogram for postoperative GBC patients, demonstrating strong discrimination and calibration. Subgroup analysis suggests that adjuvant chemotherapy benefits select high-risk patients, aiding personalized decision-making in clinical practice.